Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM3SLZK)

• Drug Name: Guanosine-5'-Monophosphate Drug Info
• Synonyms: 5'-Guanylic acid; guanylic acid; guanosine-5'-monophosphate; guanosine monophosphate; Guanosine 5'-monophosphate; 85-32-5; 5'-Gmp; Guanosine 5'-phosphate; Guanidine monophosphate; guanylate; CHEBI:17345; guanosine-phosphate; guanosine-monophosphate; Guanosine 5'-monophosphoric acid; AI3-28539; guanosine-5'-phosphate; UNII-16597955EP; EINECS 201-598-8; Guanosine 5'-phosphoric acid; CHEMBL283807; GMP; ((2R,3S,4R,5R)-5-(2-Amino-6-oxo-1H-purin-9(6H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl dihydrogen phosphate; E 626; 16597955EP

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 135398631
  ChEBI ID: CHEBI:17345
  CAS Number: CAS 85-32-5
  TTD Drug ID: DM3SLZK

Molecule-Related Drug Atlas

Drug(s) Targeting Presynaptic density protein 95 (DLG4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tat-NR2B9c	DMD6AUX	Cerebrovascular ischaemia	8B1Z	Phase 3	[3]
2-Methyl-2,4-Pentanediol	DMD45CU	Discovery agent	N.A.	Investigative	[2]
KSG-YEKLSSIESDV	DMPLFRC	Discovery agent	N.A.	Investigative	[4]
N-(3,4-Difluorophenyl)propyl-ETAV	DMF2D4O	Discovery agent	N.A.	Investigative	[4]
N-Propyl-ETAV	DMUTDNV	Discovery agent	N.A.	Investigative	[4]
N-Phenylethyl-ETAV	DM1VSO9	Discovery agent	N.A.	Investigative	[4]
N-Cyclohexylmethyl-ETAV	DMIC8Z6	Discovery agent	N.A.	Investigative	[4]
FETAV	DMO1N2T	Discovery agent	N.A.	Investigative	[4]
N-Butyl-ETAV	DMY3HEF	Discovery agent	N.A.	Investigative	[4]
N-Methyl-ETAV	DMP1EF6	Discovery agent	N.A.	Investigative	[4]

Drug(s) Targeting Phosphodiesterase 5A (PDE5A)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Tadalafil	DMJZHT1	Erectile dysfunction	HA01.1	Approved	[5]
Udenafil	DM1IQRP	Erectile dysfunction	HA01.1	Approved	[6]
Vardenafil	DMTBGW8	Erectile dysfunction	HA01.1	Approved	[7]
Dipyridamole	DMXY30O	Hypertension	BA00-BA04	Approved	[8]
Papaverine	DMCA9QP	Spasm	MB47.3	Approved	[9]
Avanafil	DM75CXN	Erectile dysfunction	HA01.1	Approved	[10]
Rhucin	DM3ADGP	Erectile dysfunction	HA01.1	Approved	[11]
ICARIIN	DMOJQGT	N. A.	N. A.	Phase 3	[12]
EXISULIND	DMBY56U	Colorectal cancer	2B91.Z	Phase 3	[13]
PF-489791	DM3C8GQ	Chronic obstructive pulmonary disease	CA22	Phase 2	[14]

Drug(s) Targeting Herpes simplex virus DNA polymerase UL30 (HSV UL30)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cytarabine	DMZD5QR	Acute lymphoblastic leukaemia	2A85	Approved	[15]
Aciclovir	DMYLOVR	Virus infection	1A24-1D9Z	Approved	[16]
Ganciclovir	DM1MBYQ	Virus infection	1A24-1D9Z	Approved	[17]
Valaciclovir	DMHKS94	Virus infection	1A24-1D9Z	Approved	[18]
Cidofovir	DMA13GD	Cytomegalovirus infection	1D82	Approved	[16]
Valganciclovir	DMS2IUH	Virus infection	1A24-1D9Z	Approved	[19]
Penciclovir	DMOUMDV	Human immunodeficiency virus infection	1C62	Approved	[20]
Famciclovir	DMJHLSD	Virus infection	1A24-1D9Z	Approved	[21]
Valacyclovir Hydrochloride	DM5I1CE	Herpes simplex virus infection	1F00	Approved	[16]
Foscavir	DM9KJLZ	Cytomegalovirus retinitis	9B72.00	Approved	[19]

Drug(s) Targeting Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US9200020, Table 3, Compound 1B	DMEARS2	N. A.	N. A.	Patented	[22]
US9200020, Table 3, Compound 2B	DMXFB5Z	N. A.	N. A.	Patented	[22]
US9200020, Table 3 compound 8	DMCLHX5	N. A.	N. A.	Patented	[22]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[2]
Formic Acid	DMNFZC6	Discovery agent	N.A.	Investigative	[2]
Pyrophosphate 2-	DMZQ75M	Discovery agent	N.A.	Investigative	[23]
Inosinic Acid	DMLR86H	Discovery agent	N.A.	Investigative	[2]
Alpha-Phosphoribosylpyrophosphoric Acid	DMT6KI7	Discovery agent	N.A.	Investigative	[23]
Carboxylic PRPP	DMCTUR1	Discovery agent	N.A.	Investigative	[2]
5--Monophosphate-9-Beta-D-Ribofuranosyl Xanthine	DMX0EAK	Discovery agent	N.A.	Investigative	[2]

Drug(s) Targeting Cytomegalovirus DNA polymerase (CMV UL54)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Guanosine	DM4T5LH	N. A.	N. A.	Phase 1	[2]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cytomegalovirus DNA polymerase (CMV UL54)	TT1U2YM	DPOL_HCMVA	Inhibitor	[2]
Herpes simplex virus DNA polymerase UL30 (HSV UL30)	TTIU7X1	DPOL_HHV11	Inhibitor	[2]
Phosphodiesterase 5A (PDE5A)	TTJ0IQB	PDE5A_HUMAN	Inhibitor	[2]
Plasmodium Hypoxanthine-guanine phosphoribosyltransferase (Malaria LACZ)	TTBL49X	HGXR_PLAFG	Inhibitor	[2]
Presynaptic density protein 95 (DLG4)	TT9PB26	DLG4_HUMAN	Inhibitor	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5123).
• [2] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [3] Treatment of stroke with a PSD-95 inhibitor in the gyrencephalic primate brain. Nature. 2012 Feb 29;483(7388):213-7.
• [4] Modified peptides as potent inhibitors of the postsynaptic density-95/N-methyl-D-aspartate receptor interaction. J Med Chem. 2008 Oct 23;51(20):6450-9.
• [5] Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis. Rheumatology (Oxford). 2009 Jun;48 Suppl 3:iii25-31.
• [6] Increased expression of the nitric oxide synthase gene and protein in corpus cavernosum by repeated dosing of udenafil in a rat model of chemical d... Asian J Androl. 2009 Jul;11(4):435-42.
• [7] The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J Am Coll Cardiol. 2002 Dec 4;40(11):2006-12.
• [8] Anti-platelet therapy: phosphodiesterase inhibitors.Br J Clin Pharmacol.2011 Oct;72(4):634-46.
• [9] Effects of icariin on cGMP-specific PDE5 and cAMP-specific PDE4 activities. Asian J Androl. 2003 Mar;5(1):15-8.
• [10] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [11] cGMP-hydrolytic activity and its inhibition by sildenafil in normal and failing human and mouse myocardium. J Pharmacol Exp Ther. 2009 Sep;330(3):884-91.
• [12] Potent inhibition of human phosphodiesterase-5 by icariin derivatives. J Nat Prod. 2008 Sep;71(9):1513-7.
• [13] Exisulind induction of apoptosis involves guanosine 3',5'-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res. 2000 Jul 1;60(13):3338-42.
• [14] Highlights of the society for medicinesresearch symposium held december 10th 2009 at the national heart and lung institute, London, UK. Drugs of the Future 2010, 35(4): 349-358.
• [15] Chromatin-associated proteins HMGB1/2 and PDIA3 trigger cellular response to chemotherapy-induced DNA damage. Mol Cancer Ther. 2009 Apr;8(4):864-72.
• [16] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [17] Application of real time polymerase chain reaction to the diagnosis and treatment of cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation. Zhonghua Xue Ye Xue Za Zhi. 2009 Feb;30(2):77-81.
• [18] Extensive oral shedding of human herpesvirus 8 in a renal allograft recipient. Oral Microbiol Immunol. 2009 Apr;24(2):109-15.
• [19] Drug targets in cytomegalovirus infection. Infect Disord Drug Targets. 2009 Apr;9(2):201-22.
• [20] Antimicrobial strategies: inhibition of viral polymerases by 3'-hydroxyl nucleosides. Drugs. 2009;69(2):151-66.
• [21] Penciclovir cream--improved topical treatment for herpes simplex infections. Skin Pharmacol Physiol. 2004 Sep-Oct;17(5):214-8.
• [22] 6-oxopurine phosphoribosyltransferase inhibitors. US9200020.
• [23] The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.